In this study, we designed a drug delivery system that used anti-GPC3 scFV-modified exosomes to load miR-26a and inhibited the proliferation and migration of GPC3-positive HCC cells in vitro. The gene discussed is GPC3; the disease is hepatocellular carcinoma.